This study is a First in Human (FIH) single ascending dose study with XAB05 to evaluate safety, tolerability, PK and exploratory markers of efficacy for XAB05 in healthy volunteers.
This study is a randomized, placebo-controlled, first in human, single ascending dose Phase 1 study